• The company also participated in the H.C. Wainwright BioConnect Conference earlier in January
• CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial
• The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. During the event, CEO John Climaco provided a corporate presentation and then participated in a moderated questions and answer session. In addition to being moderated, investors and interested parties were given the opportunity to submit questions to Mr. Climaco during the live event. The conference also accepted pre-submitted questions before the event, and the company answered as many as possible before their allotted time was up. A live video webcast of the event can be found the Events page of CNS Pharmaceuticals’ website (https://ibn.fm/Vk4cN). This webcast, featuring CNS Pharmaceuticals and Mr. Climaco, will be available for playback for one year. Earlier in January, the company participated in the H.C. Wainwright BioConnect Conference, held virtually, with Mr. Climaco also speaking. CNS Pharmaceuticals’ lead drug candidate is Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier. The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma multiforme (“GBM”), an aggressive and incurable form of cancer in the brain. More than 13,000 Americans were expected to receive a diagnosis of GBM in 2020, with the cancer accounting for 48% of all primary, malignant brain tumors. In terms of survival rates, the five-year survival rate for GBM patients is only 6.8%. The average length of survival from diagnosis is 12 to 18 months (https://ibn.fm/oX7H3). CNS Pharmaceuticals holds the worldwide exclusive license to Berubicin’s chemical compound. The company acquired all requisite data from Reata Pharmaceuticals Inc. relating to Phase I trials of Berubicin in malignant brain tumors. Roughly 44% of patients participating in this trial 14 years ago experienced significant improvement clinically. CNS Pharmaceuticals intends to explore Berubicin in other potential treatments for indications other than central nervous system cancers, including pancreatic and ovarian cancers and lymphoma. The company is also developing its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecular agents, which are believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 have demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is even evaluating the use of WP1244 in the treatment of brain cancers, pancreatic and ovarian cancer, and lymphoma. To close out 2021, CNS Pharmaceuticals received approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a pivotal Berubicin study for GBM (https://ibn.fm/JduRf). “Receiving approval from swissethics is a significant milestone for the company. Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally,” Mr. Climaco said. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well.” For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• EverGen forecasts EBITDA growth from about C$3 million in 2021 to more than C$12 million in the next 12 months from expansion of core operating assets
• EverGen stock began trading in the U.S. on the OTCQB Venture Market under ticker symbol ‘EVGIF’ on February 15, 2022
• EverGen has low-risk long term contracted or reoccurring revenue (similar to Large Cap Independent Power Producers), with two revenue sources via RNG sales and organic waste tip-fee contracts providing a high margin business with EBITDA margins of 50-60%
• In its most recent reporting, the company reported gross profit of C$1.58 million on revenue of C$1.95 million for the quarter ended September 30, 2021

EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (“RNG”), waste-to-energy, and related infrastructure projects. While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (“GHG”) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications. EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver. Portfolio Projects Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year. Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes. Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations. Market Outlook A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions. Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers. Management Team Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta. Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar. Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994. Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Cepton, Inc formally listed on the Nasdaq Capital Market on February 11, 2022, following the merger between Cepton Technologies Inc., and SPAC, Growth Capital Acquisition Corp (GCAC)
• Cepton’s CEO, Dr. Jun Pei rang the Nasdaq opening bell on Thursday, February 17, alongside CTO Dr. Mark McCord and members of both, Cepton Technologies and Growth Capital Acquisition Corp
• GCAC and Cepton arrived at a formal combination agreement on August 5, 2021, with the transaction valuing Cepton at an enterprise value of $1.5 billion

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMR(R) lidar solutions, held the opening bell ringing ceremony at Nasdaq on Thursday, February 17, 2022, after formally commencing trading on the Nasdaq Capital Market on February 11, 2022. In recognition and celebration of this important milestone, Cepton CEO and Co-Founder, Dr. Jun Pei along with CTO and Co-founder Dr. Mark McCord rang the exchange’s opening bell alongside the company’s SPAC partners, Growth Capital Acquisition Corp.’s George Syllantavos and Akis Tsirigakis. The four individuals were also joined by several Cepton team members, as well as representatives from strategic partners, investors, and advisors to mark the momentous occasion (https://ibn.fm/TRjUh). “By ringing the Nasdaq bell today, we will not only open trading for the day, but also open a new era of innovation driven towards the goal of making lidar a mainstream automotive sensor technology,” said Dr. Jun Pei, Cepton CEO. “I am thrilled to be joined by the physical and virtual presence of my talented colleagues and those who have supported us throughout all stages of Cepton’s growth. I’m excited about our journey ahead as a public company, and we remain steadfast in our mission of bringing safe and autonomous transportation to everyone.” Since its founding in 2016, Cepton has rapidly become a key player in the field of ADAS (“Advanced Driver-Assistance Systems”), the largest end-market for lidar. Lidar, which stands for ‘light detection and ranging’, provides users with the ability to map surroundings as well as measure object velocity – transforming the technology into an excellent complementary sensor for partial or fully autonomous vehicles. As far back as 2015, PWC forecast that the top five automotive original equipment manufacturers (“OEMs”) were spending upwards of $46 billion annually on research and development on autonomous vehicles, a figure which has only grown in ensuing years (https://ibn.fm/ecFWf). Now, a recently published study has suggested that the annual market for autonomous vehicles could expand to up to 110.1 thousand units by 2026, a majority of which are set to be equipped with lidar technology (https://ibn.fm/bp28F). In fact, and as of January 2022, 17 automakers around the world had announced a total of 21 lidar-equipped passenger car models, either in production or set to be launched in the near future (https://ibn.fm/NcycP). The emerging dominance of lidar as a sensor technology in autonomous vehicles has perhaps been best reflected by the exponential rise in corporate interest within the sector. In early February 2022, fellow lidar technology provider, Velodyne Lidar Inc (NASDAQ: VLDR), witnessed its share price more than double after Amazon agreed to acquire a near 16 percent stake in the company (https://ibn.fm/6N8oR); meanwhile, the CEO of automotive giant, Volkswagen recently went on the record to state that Lidar technology was integral towards attaining ‘Level 3 autonomy’ for vehicles in the future (https://ibn.fm/AXWj9). Cepton has long been operating at the forefront of lidar technology development, with the company’s relentless focus on lidar technology as well as its proprietary directional lidar technology, known as MMT(R) (“Micro Motion Technology”), leading Cepton and its tier-1 partner, Koito Manufacturing of Japan, to be awarded the largest-ever ADAS lidar series production award seen thus far by General Motors on July 13, 2021 (https://ibn.fm/vPonT). Shortly following news of the landmark contract, Ford Motor Company also revealed that they were engaging with Cepton and their custom LiDAR technology for some of the company’s vehicles’ advanced ADAS features. Following the series production award, Dr. Jun Peri commented in relation to the relative merits of lidar technology, “It’s really just a huge benefit in addition to radar and camera, and becomes an entire sensor suite that will bring cars to a higher level of safety and autonomy” (https://ibn.fm/CdzNs). Cepton Technologies’ state-of-the-art technology and robust commercial prospects were certainly at the forefront of Growth Capital Acquisition Corp’s management’s minds when opting to pursue the current business combination. The special purpose acquisition company (“SPAC”) arrived at a definitive business combination agreement with Cepton Technologies Inc., on August 5, 2021. The transaction valued Cepton at an enterprise value of approximately $1.5 billion on a cash-free, debt-free basis. Lidar technology has emerged as one of the fastest growing segments within the modern automotive industry; having been awarded the largest lidar contract the industry has seen thus far and operating at the very forefront of its field, Cepton, Inc. remains remarkably well positioned to capitalize on the sector’s burgeoning growth prospects. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Psychedelic drugs are on cusp of entering mainstream treatment for mental illness
• Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research
• Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra

A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by Cybin (NEO: CYBN) (NYSE American: CYBN). The psychedelic therapeutics company is joining forces with the Chopra Foundation to increase education and awareness of the potential use of psychedelics in supporting well-being and mental health (https://ibn.fm/IVdgc). “After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction,” the New York Times reported. “The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.” The article pointed to recent research by Rick Doblin, a pioneering psychedelics researcher, as evidence of that trajectory. “Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward . . . when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as ecstasy and molly,” the article stated. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder. “The results, coming weeks after a ‘New England Journal of Medicine’ study that highlighted the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms, have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine,” the article continued. “They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later.” This trend is almost certainly behind the new partnership between Cybin and the Chopra Foundation. Cybin has emerged as a leader in the psychedelic space, producing solid research indicating that psychedelic-assisted therapy can potentially improve the quality of life for people suffering with mental illnesses, including major depressive disorder, alcohol use disorder and anxiety disorders. The new partnership calls for the Chopra Foundation and Cybin to collaborate on efforts aimed to support education and awareness about groundbreaking research to harness the potential of psychedelic therapies in mental health. “The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” said Chopra Foundation founder, director and board chair Dr. Deepak Chopra. “Through our NeverAlone movement, we aim to combine forces with the best and brightest across businesses, policymakers, mental health professionals and others — all with the goal of building awareness, advancing scientific research and creating a global community to ensure widespread access to well-being resources. As the number of companies pursuing psychedelic-based therapies continues to grow, the foundation is particularly excited about partnering with Cybin based on its commitment to global well-being and mental health.” Noting that Cybin is one of the only companies that may truly address the needs of patients and providers, Chopra pointed out that “Cybin has cultivated a leadership position in this space based on their proprietary scientific approach that delivers the healing properties of classic psychedelics while reducing variable side effects that have prevented these natural compounds from becoming therapies in the past. . . . Their vision for improving the landscape of mental illness perfectly aligns with our goals, and we look forward to a productive partnership to further both of our missions.” Cybin CEO Doug Drysdale stated that the company is honored to partner with the Chopra Foundation and be part of the NeverAlone Initiative. “Much is understood about psychedelics, as they have been studied in academia for decades, but there is still much investigative work to be done,” he said. “At Cybin, we are using medicinal chemistry and drug-delivery technologies to build on existing clinical data and improve the patient experience by overcoming the limitations of current treatments for mental illness. We share the foundation’s pioneering spirit with regard to mental health and well-being and its goal of ensuring accessibility to much-needed treatment options to those in need.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

Companies and investors are invited to attend the Q1 2022 Virtual Investor Summit being held as a virtual event on March 8-9th, 2022.  The Investor Summit has been the largest independent conference on the East Coast for many years (formerly “The Microcap Conference”) and represents companies that are looking for a timely platform to connect with investors. The Q1 investor Summit focuses on connecting small and microcap companies with potential investors from large institutions, family businesses, private wealth and money managers. This Q1 conference will offer C level executives the opportunity to make presentations about the state of their business, updates on financials and future goals. Small and microcap companies can connect with investors through one-on-one discussions, presentations, and dialogues. “Our investors and presenting companies return to us repeatedly, owing to the immense response that they receive at these conferences.” Company Benefits 

• Scheduled meetings with qualified investors (average 8 per)
• 30-minute webcast with Q&A (average is 30+ attendees)
• Concierge meeting scheduling
• Press release distributed to the investor community in advance of the conference
• Webcast promoted on the conference website for 90 days post-conference
• Access to 800 registered attendees
• Media assets for social sharing
• Personalized tech training sessions

The Q1 Investor Summit 2022 will be organized as a virtual event with webcasts marketed on the website, giving companies optimum exposure. Investors can take part to listen to and meet and get a deep dive into potential stock investments. The seamless user experience offered at the event ensures that small-cap companies connect with investors and build long-term profitable business ties. The event has access to social media sharing, which gives the attending companies greater visibility. Connect with industry leaders and peers for a better knowledge, understanding, and higher ROI for presenting companies. To learn more, please visit https://investorsummitgroup.com/.

• Lexaria Bioscience is dedicated to applying its patented technology to pharmaceutical drug offerings to enhance their performance and speed their rate of effective use
• The company’s flagship DehydraTECH(TM) technology has delivered numerous successes in studies of its potential for treating high blood pressure and heart disease, nicotine addiction, and virus infection
• Most recently, the company reported successes in increasing the speed and effectiveness in a drug treating erectile dysfunction (“ED”) in laboratory animals
• Lexaria is preparing an investigational new drug (“IND”) application for its hypertension line of study with the aim of achieving a new drug application (“NDA”) approval from the FDA

The recent announcement that drug bio-effectiveness innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology may be useful in erectile dysfunction therapy by enhancing the speed of effectiveness of medication sildenafil (common as Viagra) follows on a number of developmental successes reported by Lexaria. DehydraTECH is a proprietary technology that changes how the body detects and absorbs drugs by combining active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applying it to a food or other type of carrier particle, synthesizing it through a dehydration procedure and rendering the resulting powder or liquid as a final product capable of being rapidly absorbed by the body without suffering reduced effectiveness through filtration by the body’s liver and digestive system. Lexaria’s testing has focused on four basic areas of application — improving the treatment of heart disease and high blood pressure, delivering nicotine in a non-smoke form, improving the effectiveness of antiviral drugs and making CBD from hemp rapidly available without inhalation. During the company’s 2021-2022 study program (https://ibn.fm/Mm3SO) a number of successes have been reported. In the HYPER-A21-1 and 2 studies the company demonstrated enhancement in the amount of CBD delivered to lab animals’ bloodstreams and brain tissue, the HYPER-H21-1 and 2 studies showed improved blood pressure reduction and reduction of blood vessel stiffness in humans, and NIC-A21-1 revealed oral nicotine delivery peak levels that were 10 to 20 times faster and 10 times higher than those of the control substances. The series VIRAL-C21-3, VIRAL-A20-2, VIRAL-MC21-1, and VIRAL-A20-3 showed inhibition of the COVID-19/SARS-CoV-2 virus, increased drug availability, and potential FDA-compliant prevention of new molecular entity (“NME”) creation utilizing antiviral drugs Remdesivir, Ebastine and Colchicine. “Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website states (https://ibn.fm/LrsOC). “Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.” Currently, all of the company’s operations are fully funded through the second quarter of 2023. Revenues grew more than 150 percent between 2020 and 2021 as Lexaria uplisted to the Nasdaq Capital Markets. The DehydraTECH-CBD human studies for treating hypertension are the most advanced as the company is in preparations for an investigational new drug (“IND”) application with the aim of filing for a new drug application (“NDA”) with the FDA. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SaaS company SRAX offers a robust suite of cutting-edge products that facilitate engagement between public companies and investors, both existing and potential
• SRAX forecasts a record first quarter of $11.5 million in revenue as part of 2022 revenue in the range of $46-$48 million
• The company bought back ~$800,000 during Q2 2021, paid a dividend in January, and optimized its cap table via the elimination of an ATM filing

There are common fundamental threads between investing 30 years ago and today, but many things are extremely different. The digital age has changed everything, and fintech companies like SRAX (NASDAQ: SRAX) have their finger on the pulse of the new modality, where investors and companies alike are all-in on transparency, social media, and big data. SRAX, recognizing the challenges public companies face in engaging and attracting investors, amassed a suite of solutions to help connect public entities with investment communities. SRAX’s premier investor intelligence and communications platform, Sequire, is specialized to provide companies all the requisite tools necessary for a public company to thrive. The turnkey tech is designed to create long-term shareholders, host company events, communicate with stakeholders, and get in front of new potential shareholders via media campaigns and investment conferences. In September 2020, SRAX acquired LD Micro, a firm that is arguably the best known data and event company serving the small and micro-cap space. From its LD Micro Index to its data sets and ultra-popular events, LD Micro is synonymous with information. Every year, hundreds of companies and thousands of investors participate in the company’s conventions, either digitally or in-person. To that point, on January 27, the company’s 2022 Sequire Metals & Mining Conference was held. The preeminent virtual event (remaining digital in the covid environment) attracted 70+ premier metals and mining stock market companies and featured key opinion leaders for speeches and discussion panels. Investors can view replays of all the presentations here. Operations are delivering increasing sales, as evidenced by bookings meeting expectations for the fourth quarter of 2021 and full year 2022 guidance in the range of $46 million to $48 million. That’s up by approximately 50% from unaudited revenue of $31.5 million in 2021. Looking exclusively at the current quarter, SRAX forecast guidance of $11.5 million, more than doubling revenue from the quarter a year prior. “The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022,” he added in providing the 2022 guidance. SRAX is executing on measures to build value for its shareholders. Last August, the company announced a new $10 million share repurchase plan, for which it bought-back about $800,000 worth of stock throughout the remainder of 2021 at an average price of $5.12 per share. Furthermore, SRAX made good on its promise to pay a dividend, giving SRAX shareholders preferred stock that translates to a cash payment or $0.01 per share. Additionally, Miglino said that the company eliminated their “At The Market” filing, a means of raising capital by selling new shares into the market, further optimizing the SRAX cap table as the company continues to look for opportunities to reward it shareholders. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Bitcoin locked on the Lightning Network has an estimated value of US$1.3 billion – indicating a bullish market contrary to the Bitcoin bear market
• LQwD has nodes active on the Lightning Network in the U.S., Germany, Singapore, and Indonesia, growing at an exponential rate by the day
• The Bitcoin Payment Ecosystem is expected to reach US$880 million by 2026
• LQwD launched its PaaS offering in November, aiming to facilitate payments worldwide

Bitcoin reached an all-time high of US$61,374.28 in October 2021, but since then the cryptocurrency’s value fluctuated significantly, dropping to US$37,928.58 in January 2022 (https://ibn.fm/OMawU). Throughout February, Bitcoin value continued to rise and fall, and it has been indicated that the cryptocurrency is currently a bear market. The same cannot be said about the Lightning Network, a layer 2 payment protocol that provides bitcoin scalability and instant transaction settlement across participating nodes with lower fees. The Network has reached an all-time high, with locked Bitcoin at an estimated value of US$1.3 billion, pointing to a bullish market for the Lightning Network (https://ibn.fm/sR2aj). One financial technology company, LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), is positioned to increase its nodes, channel, and overall value on the Lightning Network by creating an enterprise-grade infrastructure to drive bitcoin adoption as a platform-as-a-service (“PaaS”) provider. The company now has four nodes active on the Lightning Network – US-West, Germany, Singapore, and Indonesia, listed by age, oldest to newest.

• US-West: Active since October, US-West has seen some fluctuation but shows an overall 30-day upward trend. As of February 23, 2022, the node is listed with:
  • Current Capacity – 5.23134564 BTC (US$204,808.23)
  • Capacity Change (30-day) – 1.704466 BTC (US$66,797.58)
  • Current Channel Count – 91
  • Channel Count Change (30-day) – 22 (up 31.88%)
• Germany – Active since the beginning of February, LQwD’s Germany node has seen upward trending growth since going active. As of February 23, 2022, the node is listed with:
  • Current Capacity – 0.60500000 BTC (US$23,685.87)
  • Capacity Change (7-day) – 0.565000 BTC (US$22,115.5) up 1,412.50%
  • Current Channel Count – 15
  • Channel Count Change (7-day) – 11 (up 275%)
• Singapore – Also active since the beginning of February (released with Germany to expand global coverage), the Singapore node has seen great growth over a couple of weeks. As of February 23, 2022, the node is listed with:
  • Current Capacity – 0.82974242 BTC (US$32,484.58)
  • Capacity Change (7-day) – 0.719742 BTC (US$28,033.61) up 654.31%
  • Current Channel Count – 21
  • Channel Count Change (7-day) – 16 (up 320%)
• Indonesia – The Indonesian node is less than a week old, which does not provide substantial historical data to show an increase. The current capacity, channel count, and value of the node are:
  • Current Capacity – 0.07424242 BTC (US$2,906.61)
  • Current Channel Count – 1

The capacity of the nodes changes daily and can be monitored by visiting the Lightning Network Search and Analysis Engine https://1ml.com/. The Bitcoin Payment Ecosystem is expected to reach US$880 million by 2026, growing at a CAGR of 20.13% (https://ibn.fm/77Y3b). The adoption of digital wallets is expected to help drive these numbers as more people use cryptocurrency for making everyday purchases. The Lighting Network provides a platform for payments to be taken with ease – offering lower fees, quicker transaction times, and more scalability. The more nodes that come into play, the more options for international payment transfers – driving LQwD one step closer to becoming the top Lighting Network payment facilitator. LQwD released its dedicated PaaS, https://lqwd.tech/, in November 2021. The platform was designed to make access to the Lightning Network simpler and to accommodate more users looking for instantaneous transaction and settlement times, lower fees, and worldwide access to send and receive bitcoin payments. Using the LQwD platform does not require any special technical experience; it was built to be used by those who are just entering the bitcoin world, as well as by experts. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• The price of gold has increased by 6.5% to reach an 18-month high of $1,973.96
• Palladium has also increased by 5.1% in value for the third consecutive month
• Gold is proving to be the main safe-haven asset with the growing tensions
• StraightUp acknowledges a change in shareholders’ willingness to take more risks but looks to capitalize on opportunities that present themselves, specifically with the increase in the price of gold

Back in 2020, organizations worldwide had to deal with the pandemic and the geopolitical risk it presented. At that time, the situation affected investment and, more importantly, investors’ risk-taking appetite, mainly citing geostrategic, regulatory, and even political uncertainty (https://ibn.fm/6Tuu0). Fast forward to 2022, and the world is dealing with a whole different situation – the Ukraine crisis. While it is obviously focused on Eastern Europe, the evolving issue is affecting various sectors globally, and is not limited to the investment sector. StraightUp Resources (CSE: ST) (OTCQB: STUPF), an enterprise committed to mineral exploration and acquiring mineral property assets in North America, recognizes the issue and is opting to keep a close eye on the situation as it occurs. Despite its properties being located in North America, the developments in Russia and Ukraine, coupled with the former’s sanctions, are affecting its operations and its shareholders’ willingness to take more investment risks. Following the conflict, the price of gold and other precious metals has surged. Palladium, for instance, has seen a 5.1% increase in value for the third consecutive month, while gold has risen by 6.5%, reaching an 18-month high of $1,973.96 (https://ibn.fm/FCo6a). Gold has proven to be the main safe-haven asset with the growing tensions, surpassing cryptocurrencies and other assets such as Treasuries. Given that the shift for investment might understandably move more towards gold, it presents an opportunity for StraightUp, particularly since its properties are rich in gold deposits. For StraightUp, while the situation might cause fear of risk-taking, it can be expected to grow the demand for gold, increasing value for its shareholders. Everyone hopes that the situation gets resolved sooner rather than later. However, what remains certain is the impact it and other geopolitical situations around the world can have on markets and investing. StraightUp is keeping a close eye on the developments and remains focused on executing its plans for the 2022 calendar year, including new acquisitions and expansion of its market reach. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Fan Pass Live was released by Friendable in July 2020, and Artist Republik’s acquisition was completed in January 2022
• Friendable is positioned to leverage two markets – music streaming and music distribution services, capitalizing on technological advancements and the shift to digital platforms
• The global music streaming market was valued at $24.4 billion in 2020 and is expected to reach $76.9 billion by 2027
• The global music distribution services market was valued at $911.87 million in 2020 and is expected to reach $1.7 billion by 2030

In a movement of true independence for recording artists, Friendable (OTC: FDBL) is making a statement with its “anti-label” offerings – Fan Pass Live and the recently acquired Artist Republik. Three primary record labels rule the music industry – Sony Music, Warner Music, and Universal Music – each taking their revenue cut from the artists signed to them. The “anti-label” movement cuts out the contracts and high fees for distribution, leaving artists in control of their music once more. Released in July 2020, The Fan Pass Live artist platform is an online stage where artists can stream and perform music live for fans, all from a mobile device. The platform also offers artist channels, merchandise, and promotion options for artists without signing a recording contract. Fans pay a monthly subscription fee (which artists receive up to 40% of) for the Fan Pass Live experience. Additional revenue for artists comes from live show ticket sales, tips, merchandise sales and more! In January 2022, Friendable completed the acquisition of Artist Republik, a music distribution platform that provides independent artists access to all of the distribution services they would have with a recording company, without the contract. Artists can record, stream, and distribute their music without the restrictions of a recording label dictating their every move. With the combination of Fan Pass Live and Artist Republik, Friendable is creating a 360-degree all-inclusive music experience for artists worldwide. “With the decades-long struggle artists face due to the confines of a record label, along with the daily grind of finding income opportunities, we wanted to provide the opportunity for artists to regain control right from the start,” Friendable CEO Robert A. Rositano, Jr. said, according to an Instagram post celebrating the acquisition (https://ibn.fm/xt8il). Dean Rositano, President and CTO of Friendable, was quoted and says that with Artist Republik and Fan Pass Live, the company now has a 360 suite of products for independent artists to grow their fan base, as they augment their income streams, and continue engaging their fans without going the traditional route of a record label. Artist Republik Founder Nick Cianfaglione underlined that his platform single-handedly changed the face of independent music forever: “Now it’s time for us to partner with a powerful and well-resourced company, like Fan Pass, and combine forces to make double the impact in half the time.” Friendable has thus positioned itself to leverage two expanding markets – the music streaming market and music distribution services. The global music streaming market was valued at $24.4 billion in 2020 and is expected to reach $76.9 billion by 2027, growing at a CAGR of 17.8% from 2020 to 2027 (https://ibn.fm/xI3wa). The global music distribution services market was valued at $911.87 million in 2020 and is expected to reach $1.7 billion by 2030, growing at a CAGR of 6.2% from 2020 to 2030 (https://ibn.fm/vinDf). With the increase in technology and the demand for digital platforms, Friendable is staking its claim in both markets. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL